최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생명과학회지 = Journal of life science, v.29 no.12, 2019년, pp.1337 - 1344
문동규 (경상대학교병원 정형외과) , 윤정원 (경상대학교병원 구강악안면외과) , 김보규 (경상대학교 약학과) , 이아람 (경상대학교 약학과) , 문선영 (경상대학교 약학과) , 변준호 (경상대학교병원 구강악안면외과) , 황선철 (경상대학교병원 정형외과) , 우동균 (경상대학교 약학과)
Osteoporosis is characterized by a reduction in bone mass and typically manifests as an increase in fractures. Because this disease is common in elderly populations and lifespans are rapidly increasing, the incidence of osteoporosis has also grown. Most drugs currently used for osteoporosis treatmen...
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
골다공증은 무엇인가? | 골다공증은 뼈조직의 다공성이 증가하는 질환이다. 이러한 뼈의 구조적인 변화는 뼈의 밀도와 질을 감소시키며 이로 인하여 골절의 위험이 현저히 증가한다[5]. | |
골다공증의 대표적인 유발인자는? | 이러한 뼈의 구조적인 변화는 뼈의 밀도와 질을 감소시키며 이로 인하여 골절의 위험이 현저히 증가한다[5]. 골다공증의 유발 인자로는 여러 원인이 알려져 있으며, 대표적으로 나이가 증가함에 따라 골형성과 골흡수의 균형이 깨지면서 발생한다. 전 세계적으로 2억명 이상의 사람들이 골다공증으로 진단 받고 치료 중이고 미국과 유럽에서 폐경 후 여성의 약 30%가 골다공증을 가지고 있다. | |
골다공증에 의해 골절의 위험이 증가하는 원인은 무엇인가? | 골다공증은 뼈조직의 다공성이 증가하는 질환이다. 이러한 뼈의 구조적인 변화는 뼈의 밀도와 질을 감소시키며 이로 인하여 골절의 위험이 현저히 증가한다[5]. 골다공증의 유발 인자로는 여러 원인이 알려져 있으며, 대표적으로 나이가 증가함에 따라 골형성과 골흡수의 균형이 깨지면서 발생한다. |
An, T., Hao, J., Sun, S., Li, R., Yang, M., Cheng, G. and Zou, M. 2017. Efficacy of statins for osteoporosis: a systematic review and meta-analysis. Osteoporos. Int. 28, 47-57.
Armas, L. A. and Recker, R. R. 2012. Pathophysiology of osteoporosis: new mechanistic insights. Endocrinol. Metab. Clin. North Am. 41, 475-486.
Berebichez-Fridman, R., Gomez-Garcia, R., Granados-Montiel, J., Berebichez-Fastlicht, E., Olivos-Meza, A., Granados, J., Velasquillo, C. and Ibarra, C. 2017. The holy grail of orthopedic surgery: mesenchymal stem cells-their current uses and potential applications. Stem Cells Int. 2017, 2638305.
Bu, D. X., Griffin, G. and Lichtman, A. H. 2011. Mechanisms for the anti-inflammatory effects of statins. Curr. Opin. Lipidol. 22, 165-170.
Campos, R. M., de Piano, A., da Silva, P. L., Carnier, J., Sanches, P. L., Corgosinho, F. C., Masquio, D. C., Lazaretti-Castro, M., Oyama, L. M., Nascimento, C. M., Tock, L., de Mello, M. T., Tufik, S. and Damaso, A. R. 2012. The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine 42, 146-156.
Choudhery, M. S., Badowski, M., Muise, A., Pierce, J. and Harris, D. T. 2014. Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation. J. Transl. Med. 12, 8.
Chung, J. E., Park, J. H., Yun, J. W., Kang, Y. H., Park, B. W., Hwang, S. C., Cho, Y. C., Sung, I. Y., Woo, D. K. and Byun, J. H. 2016. Cultured human periosteum-derived cells can differentiate into osteoblasts in a perioxisome proliferator-activated receptor gamma-mediated fashion via bone morphogenetic protein signaling. Int. J. Med. Sci. 13, 806-818.
Coxon, F. P., Thompson, K., Roelofs, A. J., Ebetino, F. H. and Rogers, M. J. 2008. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42, 848-860.
De Bari, C., Dell'Accio, F. and Luyten, F. P. 2001. Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum. 44, 85-95.
De Bari, C., Dell'Accio, F., Vanlauwe, J., Eyckmans, J., Khan, I. M., Archer, C. W., Jones, E. A., McGonagle, D., Mitsiadis, T. A., Pitzalis, C. and Luyten, F. P. 2006. Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheum. 54, 1209-1221.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D. and Horwitz, E. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 8, 315-317.
El-Nabarawi, N., El-Wakd, M. and Salem, M. 2017. Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study. Drug Des. Devel. Ther. 11, 1383-1391.
Ettinger, B., Burr, D. B. and Ritchie, R. O. 2013. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 55, 495-500.
Ferreira Junior, D. B., Pizziolo, V. R., Oliveira, T. T., Matta, S., Piccolo, M. S. and Queiroz, J. H. 2018. Biometric, histomorphometric, and biochemical profile in atorvastatin calcium treatment of female rats with dexamethasone-induced osteoporosis. Rev. Bras. Ortop. 53, 607-613.
Ferretti, C. and Mattioli-Belmonte, M. 2014. Periosteum derived stem cells for regenerative medicine proposals: Boosting current knowledge. World J. Stem Cells 6, 266-277.
Hanayama, R., Shimizu, H., Nakagami, H., Osako, M. K., Makino, H., Kunugiza, Y., Tomita, T., Tsukamoto, I., Yoshikawa, H., Rakugi, H. and Morishita, R. 2009. Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action. Int. J. Mol. Med. 23, 581-588.
Hernandez-Vallejo, S. J., Beaupere, C., Larghero, J., Capeau, J. and Lagathu, C. 2013. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell 12, 955-965.
Hwang, D. K. and Choi, H. J. 2010. The relationship between low bone mass and metabolic syndrome in Korean women. Osteoporos. Int. 21, 425-431.
Jadhav, S. B. and Jain, G. K. 2006. Statins and osteoporosis: new role for old drugs. J. Pharm. Pharmacol. 58, 3-18.
Jain, M. K. and Ridker, P. M. 2005. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4, 977-987.
Khosla, S. 2001. Minireview: the OPG/RANKL/RANK system. Endocrinology 142, 5050-5055.
Mendoza, S., Noa, M., Mas, R. and Mendoza, N. 2005. Comparison of the effects of D-003, a mixture of high-molecular-weight aliphatic acids from sugarcane wax, and pravastatin on bones and osteoclast apoptosis of ovariectomized rats. Drugs Exp. Clin. Res. 31, 181-191.
Mohamed, M. T., Abuelezz, S. A., Atalla, S. S., El Aziz, L. F. A. and Gorge, S. S. 2017. The anti-osteoporotic and anti- atherogenic effects of alendronate and simvastatin in ovariectomized rats fed high fat diet: A comparative study of combination therapy versus monotherapy. Biomed. Pharmacother. 89, 1115-1124.
Monjo, M., Rubert, M., Ellingsen, J. E. and Lyngstadaas, S. P. 2010. Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells. Cell Physiol. Biochem. 26, 647-656.
Mundy, G., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B., Zhao, M. and Gutierrez, G. 1999. Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946-1949.
Nakashima, Y. and Haneji, T. 2013. Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss. PLoS One 8, e72033.
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B., Grines, C. L. and DeMaria, A. N. 2004. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 291, 1071-1080.
Oda, Y., Sasaki, H., Miura, T., Takanashi, T., Furuya, Y., Yoshinari, M. and Yajima, Y. 2018. Bone marrow stromal cells from low-turnover osteoporotic mouse model are less sensitive to the osteogenic effects of fluvastatin. PLoS One 13, e0202857.
Ohnaka, K., Shimoda, S., Nawata, H., Shimokawa, H., Kaibuchi, K., Iwamoto, Y. and Takayanagi, R. 2001. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem. Biophys. Res. Commun. 287, 337-342.
Pagkalos, J., Cha, J. M., Kang, Y., Heliotis, M., Tsiridis, E. and Mantalaris, A. 2010. Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J. Bone Miner. Res. 25, 2470-2478.
Pelton, K., Krieder, J., Joiner, D., Freeman, M. R., Goldstein, S. A. and Solomon, K. R. 2012. Hypercholesterolemia promotes an osteoporotic phenotype. Am. J. Pathol. 181, 928-936.
Pirih, F., Lu, J., Ye, F., Bezouglaia, O., Atti, E., Ascenzi, M. G., Tetradis, S., Demer, L., Aghaloo, T. and Tintut, Y. 2012. Adverse effects of hyperlipidemia on bone regeneration and strength. J. Bone Miner. Res. 27, 309-318.
Qadir, F., Alam, S. M., Zehra, T., Mehmood, A. and Siddiqi, A. Q. 2016. Role of pitavastatin in prevention of osteopenic changes in ovariectomized rats. J. Coll. Physicians Surg. Pak. 26, 41-45.
Reginster, J. Y. and Burlet, N. 2006. Osteoporosis: a still increasing prevalence. Bone 38, S4-9.
Rizzoli, R., Akesson, K., Bouxsein, M., Kanis, J. A., Napoli, N., Papapoulos, S., Reginster, J. Y. and Cooper, C. 2011. Subtrochanteric fractures after long-term treatment with bisphosphonates: a european society on clinical and economic aspects of osteoporosis and osteoarthritis, and international osteoporosis foundation working group report. Osteoporos. Int. 22, 373-390.
Ruan, F., Zheng, Q. and Wang, J. 2012. Mechanisms of bone anabolism regulated by statins. Biosci. Rep. 32, 511-519.
Shahrezaee, M., Oryan, A., Bastami, F., Hosseinpour, S., Shahrezaee, M. H. and Kamali, A. 2018. Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats. Endocrine 60, 138-150.
Sobolev, M. S., Faitelson, A. V., Gudyrev, O. S., Rajkumar, D. S. R., Dubrovin, G. M., Anikanov, A. V., Koklina, N. U. and Chernomortseva, E. S. 2018. Study of endothelio- and osteoprotective effects of combination of rosuvastatin with L-norvaline in experiment. J. Osteoporos. 2018, 1585749.
Tadrous, M., Wong, L., Mamdani, M. M., Juurlink, D. N., Krahn, M. D., Levesque, L. E. and Cadarette, S. M. 2014. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos. Int. 25, 1225-1235.
Takayama, T., Hiro, T., Yamagishi, M., Daida, H., Hirayama, A., Saito, S., Yamaguchi, T. and Matsuzaki, M. 2009. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ. J. 73, 2110-2117.
Wang, D., Liu, N., Gao, Y., Li, P. and Tian, M. 2014. Association between metabolic syndrome and osteoporotic fracture in middle-aged and elderly Chinese peoples. Cell Biochem. Biophys. 70, 1297-1303.
Wang, Y. L., Hong, A., Yen, T. H. and Hong, H. H. 2018. Isolation of mesenchymal stem cells from human alveolar periosteum and effects of vitamin D on osteogenic activity of periosteum-derived cells. J. Vis. Exp. 135, E57166.
Wong, S. K., Chin, K. Y., Suhaimi, F. H., Ahmad, F. and Ima-Nirwana, S. 2016. The relationship between metabolic syndrome and osteoporosis: A review. Nutrients 8, 347
Xie, Y., Liu, C., Huang, H., Huang, J., Deng, A., Zou, P. and Tan, X. 2018. Bone-targeted delivery of simvastatin-loaded PEG-PLGA micelles conjugated with tetracycline for osteoporosis treatment. Drug Deliv. Transl. Res. 8, 1090-1102.
Yamaguchi, T., Sugimoto, T., Yano, S., Yamauchi, M., Sowa, H., Chen, Q. and Chihara, K. 2002. Plasma lipids and osteoporosis in postmenopausal women. Endocr. J. 49, 211-217.
Yang, P. M., Liu, Y. L., Lin, Y. C., Shun, C. T., Wu, M. S. and Chen, C. C. 2010. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 70, 7699-7709.
Yaturu, S., Humphrey, S., Landry, C. and Jain, S. K. 2009. Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. Med. Sci. Monit. 15, CR5-9.
Zhou, H., Xie, Y., Baloch, Z., Shi, Q., Huo, Q. and Ma, T. 2017. The effect of atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (HMG-CoA), on the prevention of osteoporosis in ovariectomized rabbits. J. Bone Miner. Metab. 35, 245-254.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.